Review article: acute severe ulcerative colitis – evidence‐based consensus statements

Summary Background Acute severe ulcerative colitis (ASUC) is a potentially life‐threatening complication of ulcerative colitis. Aim To develop consensus statements based on a systematic review of the literature of the management of ASUC to improve patient outcome. Methods Following a literature revi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alimentary pharmacology & therapeutics 2016-07, Vol.44 (2), p.127-144
Hauptverfasser: Chen, J.‐H., Andrews, J. M., Kariyawasam, V., Moran, N., Gounder, P., Collins, G., Walsh, A. J., Connor, S., Lee, T. W. T., Koh, C. E., Chang, J., Paramsothy, S., Tattersall, S., Lemberg, D. A., Radford‐Smith, G., Lawrance, I. C., McLachlan, A., Moore, G. T., Corte, C., Katelaris, P., Leong, R. W.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 144
container_issue 2
container_start_page 127
container_title Alimentary pharmacology & therapeutics
container_volume 44
creator Chen, J.‐H.
Andrews, J. M.
Kariyawasam, V.
Moran, N.
Gounder, P.
Collins, G.
Walsh, A. J.
Connor, S.
Lee, T. W. T.
Koh, C. E.
Chang, J.
Paramsothy, S.
Tattersall, S.
Lemberg, D. A.
Radford‐Smith, G.
Lawrance, I. C.
McLachlan, A.
Moore, G. T.
Corte, C.
Katelaris, P.
Leong, R. W.
description Summary Background Acute severe ulcerative colitis (ASUC) is a potentially life‐threatening complication of ulcerative colitis. Aim To develop consensus statements based on a systematic review of the literature of the management of ASUC to improve patient outcome. Methods Following a literature review, the Delphi method was used to develop the consensus statements. A steering committee, based in Australia, generated the statements of interest. Three rounds of anonymous voting were carried out to achieve the final results. Acceptance of statements was pre‐determined by ≥80% votes in ‘complete agreement’ or ‘agreement with minor reservation’. Results Key recommendations include that patients with ASUC should be: hospitalised, undergo unprepared flexible sigmoidoscopy to assess severity and to exclude cytomegalovirus colitis, and be provided with venous thromboembolism prophylaxis and intravenous hydrocortisone 100 mg three or four times daily with close monitoring by a multidisciplinary team. Rescue therapy such as infliximab or ciclosporin should be started if insufficient response by day 3, and colectomy considered if no response to 7 days of rescue therapy or earlier if deterioration. With such an approach, it is expected that colectomy rate during admission will be below 30% and mortality less than 1% in specialist centres. Conclusion These evidenced‐based consensus statements on acute severe ulcerative colitis, developed by a multidisciplinary group, provide up‐to‐date best practice recommendations that improve and harmonise management as well as provide auditable quality assessments.
doi_str_mv 10.1111/apt.13670
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1797231690</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1797231690</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4260-ff28e847f75393432766537b1c939eaf7e8ba3e8da4daf8ae7814e179be0f5413</originalsourceid><addsrcrecordid>eNp1kLtOwzAUQC0EoqUw8AMoIwxp_UjihK2qeEmVQKgMTJbjXEtBeRTbadWtn4DEH_ZLMKSwcZc73HPPcBA6J3hM_Ezk0o0JSzg-QEO_45BilhyiIaZJFtKUsAE6sfYNY-wZeowGlFOasCgaotdnWJWwDqRxpargOpCqcxBYWIGBoKsUGOnKFQSqrUpX2mC3_Qz8SwGNgt32I5cWCn9sLDS2s4F10kENjbOn6EjLysLZfo_Qy-3NYnYfzh_vHmbTeagimuBQa5pCGnHNY5axiFGeJDHjOVEZy0BqDmkuGaSFjAqpUwk8JREQnuWAdRwRNkKXvXdp2vcOrBN1aRVUlWyg7azwKKeMJBn26FWPKtNaa0CLpSlraTaCYPFdUviS4qekZy_22i6vofgjf9N5YNID67KCzf8mMX1a9MoveXp_2Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1797231690</pqid></control><display><type>article</type><title>Review article: acute severe ulcerative colitis – evidence‐based consensus statements</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Chen, J.‐H. ; Andrews, J. M. ; Kariyawasam, V. ; Moran, N. ; Gounder, P. ; Collins, G. ; Walsh, A. J. ; Connor, S. ; Lee, T. W. T. ; Koh, C. E. ; Chang, J. ; Paramsothy, S. ; Tattersall, S. ; Lemberg, D. A. ; Radford‐Smith, G. ; Lawrance, I. C. ; McLachlan, A. ; Moore, G. T. ; Corte, C. ; Katelaris, P. ; Leong, R. W.</creator><creatorcontrib>Chen, J.‐H. ; Andrews, J. M. ; Kariyawasam, V. ; Moran, N. ; Gounder, P. ; Collins, G. ; Walsh, A. J. ; Connor, S. ; Lee, T. W. T. ; Koh, C. E. ; Chang, J. ; Paramsothy, S. ; Tattersall, S. ; Lemberg, D. A. ; Radford‐Smith, G. ; Lawrance, I. C. ; McLachlan, A. ; Moore, G. T. ; Corte, C. ; Katelaris, P. ; Leong, R. W. ; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group</creatorcontrib><description>Summary Background Acute severe ulcerative colitis (ASUC) is a potentially life‐threatening complication of ulcerative colitis. Aim To develop consensus statements based on a systematic review of the literature of the management of ASUC to improve patient outcome. Methods Following a literature review, the Delphi method was used to develop the consensus statements. A steering committee, based in Australia, generated the statements of interest. Three rounds of anonymous voting were carried out to achieve the final results. Acceptance of statements was pre‐determined by ≥80% votes in ‘complete agreement’ or ‘agreement with minor reservation’. Results Key recommendations include that patients with ASUC should be: hospitalised, undergo unprepared flexible sigmoidoscopy to assess severity and to exclude cytomegalovirus colitis, and be provided with venous thromboembolism prophylaxis and intravenous hydrocortisone 100 mg three or four times daily with close monitoring by a multidisciplinary team. Rescue therapy such as infliximab or ciclosporin should be started if insufficient response by day 3, and colectomy considered if no response to 7 days of rescue therapy or earlier if deterioration. With such an approach, it is expected that colectomy rate during admission will be below 30% and mortality less than 1% in specialist centres. Conclusion These evidenced‐based consensus statements on acute severe ulcerative colitis, developed by a multidisciplinary group, provide up‐to‐date best practice recommendations that improve and harmonise management as well as provide auditable quality assessments.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.13670</identifier><identifier>PMID: 27226344</identifier><language>eng</language><publisher>England</publisher><subject>Australia ; Colectomy - methods ; Colitis, Ulcerative - drug therapy ; Colitis, Ulcerative - therapy ; Consensus ; Cyclosporine - therapeutic use ; Hospitalization ; Humans ; Infliximab - therapeutic use ; Venous Thromboembolism - prevention &amp; control</subject><ispartof>Alimentary pharmacology &amp; therapeutics, 2016-07, Vol.44 (2), p.127-144</ispartof><rights>2016 John Wiley &amp; Sons Ltd</rights><rights>2016 John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4260-ff28e847f75393432766537b1c939eaf7e8ba3e8da4daf8ae7814e179be0f5413</citedby><cites>FETCH-LOGICAL-c4260-ff28e847f75393432766537b1c939eaf7e8ba3e8da4daf8ae7814e179be0f5413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fapt.13670$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fapt.13670$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27226344$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, J.‐H.</creatorcontrib><creatorcontrib>Andrews, J. M.</creatorcontrib><creatorcontrib>Kariyawasam, V.</creatorcontrib><creatorcontrib>Moran, N.</creatorcontrib><creatorcontrib>Gounder, P.</creatorcontrib><creatorcontrib>Collins, G.</creatorcontrib><creatorcontrib>Walsh, A. J.</creatorcontrib><creatorcontrib>Connor, S.</creatorcontrib><creatorcontrib>Lee, T. W. T.</creatorcontrib><creatorcontrib>Koh, C. E.</creatorcontrib><creatorcontrib>Chang, J.</creatorcontrib><creatorcontrib>Paramsothy, S.</creatorcontrib><creatorcontrib>Tattersall, S.</creatorcontrib><creatorcontrib>Lemberg, D. A.</creatorcontrib><creatorcontrib>Radford‐Smith, G.</creatorcontrib><creatorcontrib>Lawrance, I. C.</creatorcontrib><creatorcontrib>McLachlan, A.</creatorcontrib><creatorcontrib>Moore, G. T.</creatorcontrib><creatorcontrib>Corte, C.</creatorcontrib><creatorcontrib>Katelaris, P.</creatorcontrib><creatorcontrib>Leong, R. W.</creatorcontrib><creatorcontrib>IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group</creatorcontrib><title>Review article: acute severe ulcerative colitis – evidence‐based consensus statements</title><title>Alimentary pharmacology &amp; therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary Background Acute severe ulcerative colitis (ASUC) is a potentially life‐threatening complication of ulcerative colitis. Aim To develop consensus statements based on a systematic review of the literature of the management of ASUC to improve patient outcome. Methods Following a literature review, the Delphi method was used to develop the consensus statements. A steering committee, based in Australia, generated the statements of interest. Three rounds of anonymous voting were carried out to achieve the final results. Acceptance of statements was pre‐determined by ≥80% votes in ‘complete agreement’ or ‘agreement with minor reservation’. Results Key recommendations include that patients with ASUC should be: hospitalised, undergo unprepared flexible sigmoidoscopy to assess severity and to exclude cytomegalovirus colitis, and be provided with venous thromboembolism prophylaxis and intravenous hydrocortisone 100 mg three or four times daily with close monitoring by a multidisciplinary team. Rescue therapy such as infliximab or ciclosporin should be started if insufficient response by day 3, and colectomy considered if no response to 7 days of rescue therapy or earlier if deterioration. With such an approach, it is expected that colectomy rate during admission will be below 30% and mortality less than 1% in specialist centres. Conclusion These evidenced‐based consensus statements on acute severe ulcerative colitis, developed by a multidisciplinary group, provide up‐to‐date best practice recommendations that improve and harmonise management as well as provide auditable quality assessments.</description><subject>Australia</subject><subject>Colectomy - methods</subject><subject>Colitis, Ulcerative - drug therapy</subject><subject>Colitis, Ulcerative - therapy</subject><subject>Consensus</subject><subject>Cyclosporine - therapeutic use</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Infliximab - therapeutic use</subject><subject>Venous Thromboembolism - prevention &amp; control</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kLtOwzAUQC0EoqUw8AMoIwxp_UjihK2qeEmVQKgMTJbjXEtBeRTbadWtn4DEH_ZLMKSwcZc73HPPcBA6J3hM_Ezk0o0JSzg-QEO_45BilhyiIaZJFtKUsAE6sfYNY-wZeowGlFOasCgaotdnWJWwDqRxpargOpCqcxBYWIGBoKsUGOnKFQSqrUpX2mC3_Qz8SwGNgt32I5cWCn9sLDS2s4F10kENjbOn6EjLysLZfo_Qy-3NYnYfzh_vHmbTeagimuBQa5pCGnHNY5axiFGeJDHjOVEZy0BqDmkuGaSFjAqpUwk8JREQnuWAdRwRNkKXvXdp2vcOrBN1aRVUlWyg7azwKKeMJBn26FWPKtNaa0CLpSlraTaCYPFdUviS4qekZy_22i6vofgjf9N5YNID67KCzf8mMX1a9MoveXp_2Q</recordid><startdate>201607</startdate><enddate>201607</enddate><creator>Chen, J.‐H.</creator><creator>Andrews, J. M.</creator><creator>Kariyawasam, V.</creator><creator>Moran, N.</creator><creator>Gounder, P.</creator><creator>Collins, G.</creator><creator>Walsh, A. J.</creator><creator>Connor, S.</creator><creator>Lee, T. W. T.</creator><creator>Koh, C. E.</creator><creator>Chang, J.</creator><creator>Paramsothy, S.</creator><creator>Tattersall, S.</creator><creator>Lemberg, D. A.</creator><creator>Radford‐Smith, G.</creator><creator>Lawrance, I. C.</creator><creator>McLachlan, A.</creator><creator>Moore, G. T.</creator><creator>Corte, C.</creator><creator>Katelaris, P.</creator><creator>Leong, R. W.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201607</creationdate><title>Review article: acute severe ulcerative colitis – evidence‐based consensus statements</title><author>Chen, J.‐H. ; Andrews, J. M. ; Kariyawasam, V. ; Moran, N. ; Gounder, P. ; Collins, G. ; Walsh, A. J. ; Connor, S. ; Lee, T. W. T. ; Koh, C. E. ; Chang, J. ; Paramsothy, S. ; Tattersall, S. ; Lemberg, D. A. ; Radford‐Smith, G. ; Lawrance, I. C. ; McLachlan, A. ; Moore, G. T. ; Corte, C. ; Katelaris, P. ; Leong, R. W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4260-ff28e847f75393432766537b1c939eaf7e8ba3e8da4daf8ae7814e179be0f5413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Australia</topic><topic>Colectomy - methods</topic><topic>Colitis, Ulcerative - drug therapy</topic><topic>Colitis, Ulcerative - therapy</topic><topic>Consensus</topic><topic>Cyclosporine - therapeutic use</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Infliximab - therapeutic use</topic><topic>Venous Thromboembolism - prevention &amp; control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, J.‐H.</creatorcontrib><creatorcontrib>Andrews, J. M.</creatorcontrib><creatorcontrib>Kariyawasam, V.</creatorcontrib><creatorcontrib>Moran, N.</creatorcontrib><creatorcontrib>Gounder, P.</creatorcontrib><creatorcontrib>Collins, G.</creatorcontrib><creatorcontrib>Walsh, A. J.</creatorcontrib><creatorcontrib>Connor, S.</creatorcontrib><creatorcontrib>Lee, T. W. T.</creatorcontrib><creatorcontrib>Koh, C. E.</creatorcontrib><creatorcontrib>Chang, J.</creatorcontrib><creatorcontrib>Paramsothy, S.</creatorcontrib><creatorcontrib>Tattersall, S.</creatorcontrib><creatorcontrib>Lemberg, D. A.</creatorcontrib><creatorcontrib>Radford‐Smith, G.</creatorcontrib><creatorcontrib>Lawrance, I. C.</creatorcontrib><creatorcontrib>McLachlan, A.</creatorcontrib><creatorcontrib>Moore, G. T.</creatorcontrib><creatorcontrib>Corte, C.</creatorcontrib><creatorcontrib>Katelaris, P.</creatorcontrib><creatorcontrib>Leong, R. W.</creatorcontrib><creatorcontrib>IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology &amp; therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, J.‐H.</au><au>Andrews, J. M.</au><au>Kariyawasam, V.</au><au>Moran, N.</au><au>Gounder, P.</au><au>Collins, G.</au><au>Walsh, A. J.</au><au>Connor, S.</au><au>Lee, T. W. T.</au><au>Koh, C. E.</au><au>Chang, J.</au><au>Paramsothy, S.</au><au>Tattersall, S.</au><au>Lemberg, D. A.</au><au>Radford‐Smith, G.</au><au>Lawrance, I. C.</au><au>McLachlan, A.</au><au>Moore, G. T.</au><au>Corte, C.</au><au>Katelaris, P.</au><au>Leong, R. W.</au><aucorp>IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Review article: acute severe ulcerative colitis – evidence‐based consensus statements</atitle><jtitle>Alimentary pharmacology &amp; therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2016-07</date><risdate>2016</risdate><volume>44</volume><issue>2</issue><spage>127</spage><epage>144</epage><pages>127-144</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary Background Acute severe ulcerative colitis (ASUC) is a potentially life‐threatening complication of ulcerative colitis. Aim To develop consensus statements based on a systematic review of the literature of the management of ASUC to improve patient outcome. Methods Following a literature review, the Delphi method was used to develop the consensus statements. A steering committee, based in Australia, generated the statements of interest. Three rounds of anonymous voting were carried out to achieve the final results. Acceptance of statements was pre‐determined by ≥80% votes in ‘complete agreement’ or ‘agreement with minor reservation’. Results Key recommendations include that patients with ASUC should be: hospitalised, undergo unprepared flexible sigmoidoscopy to assess severity and to exclude cytomegalovirus colitis, and be provided with venous thromboembolism prophylaxis and intravenous hydrocortisone 100 mg three or four times daily with close monitoring by a multidisciplinary team. Rescue therapy such as infliximab or ciclosporin should be started if insufficient response by day 3, and colectomy considered if no response to 7 days of rescue therapy or earlier if deterioration. With such an approach, it is expected that colectomy rate during admission will be below 30% and mortality less than 1% in specialist centres. Conclusion These evidenced‐based consensus statements on acute severe ulcerative colitis, developed by a multidisciplinary group, provide up‐to‐date best practice recommendations that improve and harmonise management as well as provide auditable quality assessments.</abstract><cop>England</cop><pmid>27226344</pmid><doi>10.1111/apt.13670</doi><tpages>18</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0269-2813
ispartof Alimentary pharmacology & therapeutics, 2016-07, Vol.44 (2), p.127-144
issn 0269-2813
1365-2036
language eng
recordid cdi_proquest_miscellaneous_1797231690
source Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Australia
Colectomy - methods
Colitis, Ulcerative - drug therapy
Colitis, Ulcerative - therapy
Consensus
Cyclosporine - therapeutic use
Hospitalization
Humans
Infliximab - therapeutic use
Venous Thromboembolism - prevention & control
title Review article: acute severe ulcerative colitis – evidence‐based consensus statements
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T23%3A40%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Review%20article:%20acute%20severe%20ulcerative%20colitis%20%E2%80%93%20evidence%E2%80%90based%20consensus%20statements&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Chen,%20J.%E2%80%90H.&rft.aucorp=IBD%20Sydney%20Organisation%20and%20the%20Australian%20Inflammatory%20Bowel%20Diseases%20Consensus%20Working%20Group&rft.date=2016-07&rft.volume=44&rft.issue=2&rft.spage=127&rft.epage=144&rft.pages=127-144&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.13670&rft_dat=%3Cproquest_cross%3E1797231690%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1797231690&rft_id=info:pmid/27226344&rfr_iscdi=true